For women with metastatic breast cancer, treatment with an encapsulated form of the drug doxorubicin offers a well-tolerated option for maintenance therapy that delays progression and offers benefits in terms of survival, new results show. Spanish researchers led by Dr. Emilio Alba have been studying the effects of pegylated liposomal doxorubicin in a group of 155 women who had already been treated with chemotherapy.
More...